These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1531153)

  • 21. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M
    Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis.
    Webster A; Wilson AP; Williams AH; Treasure T; Grüneberg RN
    Postgrad Med J; 1987 Aug; 63(742):621-4. PubMed ID: 2962071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the safety profile of teicoplanin.
    Davey PG; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():69-73. PubMed ID: 1829079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
    Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.
    Kureishi A; Jewesson PJ; Rubinger M; Cole CD; Reece DE; Phillips GL; Smith JA; Chow AW
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2246-52. PubMed ID: 1839490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiological properties of teicoplanin.
    Greenwood D
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():1-13. PubMed ID: 2965119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teicoplanin: an investigational glycopeptide antibiotic.
    Pryka RD; Rodvold KA; Rotschafer JC
    Clin Pharm; 1988 Sep; 7(9):647-58. PubMed ID: 2977108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
    Chisari G
    Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci.
    Felmingham D; Solomonides K; O'Hare MD; Wilson AP; Grüneberg RN
    J Antimicrob Chemother; 1987 Oct; 20(4):609-10. PubMed ID: 2960645
    [No Abstract]   [Full Text] [Related]  

  • 34. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
    Brown DF; Courvalin P
    Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.
    Watanakunakorn C
    J Antimicrob Chemother; 1988 Sep; 22(3):321-4. PubMed ID: 2972670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation of in vitro activity of teicoplanin and vancomycin against coagulase negative methicillin resistant staphylococci isolated from high-risk patients.
    Battista C; Panza N; Chiurazzi B; Romano A; Pacilio G; Amato G; Gargiulo F; Bolletti Censi M; Bocchetti M
    Biomed Pharmacother; 1991; 45(1):43. PubMed ID: 1828377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.